Member Info for Doc3

Certainly they’ve saved money on the financial report.

Much more appropriate than the previous expensive photography exercises.

Bland. It looks like it’s been written in house.

More. The going concern section still sounds dire.

Prelims due June. As on website.

So soon.

All updated.

Looks good.

Certainly what’s left of market is not impressed.

Https://link.springer.com/article/10.1186/s40164-026-00774-4

Another. Ct dna/ctc using Parsortix because it is epitope independent.

I honestly can’t emphasise how important this is.

It’s perfect for interface with any ct dna assay.

It could be rolled out soon to make any of those tests better.

We have seen it before in Parsortix plus.

Https://wp-cellbxhealth-prod-2026.s3.eu-west-2.amazonaws.com/media/2024/08/2024-Saini-A-comparative-study-of-CTC-isolation-technologies-TCD.pdf

This is important. New version beta testing. Totally automated, faster, better for ctc/ct dna assays.

Powerful endorsement

https://www.nature.com/articles/s41598-026-47094-5

Https://www.sciencedirect.com/science/article/pii/S2950195426000056

I think this is important

Brett S disappeared from website.

P Collins confirmed as exec.

New photos all round.

I have no idea.

But. They did go to the JP Morgan conf last week.

It’s invite only.

It’s a place where deals are finalised.

They have been quiet on comms before and since.

Wasn’t that the ESOT transaction as RNS?

Did you purchase a different 2.8 million shares?

Seems a coincidence?

Looking at it on website they have updated.

Conifer 29%, Dermot K 15%,

Have new shares all been issued?

If so why no TR1?

Why?

What valuation do you think EC?

AN always talked in billions.

A billion would almost be 100p, so 100x SP.

Is that realistic?

There you go.

Not oversubscribed then.

Presumably because most retail investors have almost no money left and less appetite to lose yet more.

The key question today is has the retail offer got away? Has it been over subscribed?

I note it did not close early.

Cavendish note.

4p target.

https://cellbxhealth.com/wp-content/uploads/2025/11/Cavendish-CLBX@LN-CelLBxHealth-Accelerating-the-commercial-ramp-up-of-Pa-1.pdf

Great. 6p less than their last note. 4p. Such an unbelievable destruction of value

50 million market cap?

Maybe.,

Would need 10 million revenue a year and the return of optimism to the sector.

Both look unlikely.

That said he did linger on sale. If it got to 3p and then an offer maybe 6p.

Probably not though. Optimism in this company is historically a costly mistake